Browsing Tag
IL-2 agonist
1 post
Breakthrough REZOLVE-AD results position Rezpegaldesleukin as a potential first-in-class IL-2 Treg therapy for atopic dermatitis and asthma
Rezpegaldesleukin delivers strong dual skin and asthma results in the REZOLVE-AD study — find out how Nektar Therapeutics plans to advance its IL-2 Treg platform in 2026.